Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ohoud Aljuhani has a total of 384 co-authors. Here are the top co-authors by number of shared publications:

  • Khalid Al Sulaiman

    College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

    25 shared publications
  • Ramesh Vishwakarma

    Norwich Clinical Trial Unit Norwich Medical School, University of East Anglia Norwich UK

    17 shared publications
  • Ghazwa B. Korayem

    Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

    9 shared publications
  • Aisha Alharbi

    Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia

    8 shared publications
  • Hisham A. Badreldin

    Pharmaceutical Care Services, King Abdulaziz Medical City, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

    7 shared publications
  • Khalid Eljaaly

    Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

    7 shared publications

Latest Publications

  • Open Access

    Length of hospitalization in intensive care units: A cross-sectional study

    by Reema Karasneh, Sayer Al-Azzam, Karem H. Alzoubi, Lana Rababah, Dua’A Mohammad, Dania Rahhal, Louai Alsaloumi, Suad Kabbaha, Mamoon A. Aldeyab, Ohoud Aljuhani

    Prolonged hospitalizations in intensive care units (ICUs) due to critical conditions are a significant challenge to the healthcare system. The primary objective within the ICU is to reduce the length of stay (LOS), which ultimately could enhance the quality of healthcare, minimize complications, and reduce healthcare-associated costs. This study aims to identify factors affecting the LOS in ICUs. This is a retrospective cross-sectional study that utilized electronic records from a tertiary hospital, analyzing data from 7628 ICU admissions between 2012 and 2022. A total of 7628 ICU patients were included, with a mean stay of 4.3 ± 7.3 days, 33.7% remained ≥ 3 days. The majority of the included patients were males (59.12%) and aged above 60 years (53.03%). Several factors were significantly associated with prolonged ICU stay including sepsis (odds ratio [OR] = 5.56, 95% confidence interval [CI]: 3.42–9.04, P < .001), receiving nutrition via a nasogastric (NG) tube (OR = 2.42, 95% CI: 1.88–3.13, P <  .001), and receiving antibiotics (OR = 2.07, 95%CI: 1.81–2.38, P < .001). In generalized linear model analysis, tracheostomy, sepsis and mechanical ventilation were strongest predictors of prolonged ICU stay (Exp(B) = 3.33, 1.63, 1.60), respectively, P < .001). This study identified several factors significantly associated with LOS in the ICU. Illness severity, intensity of supportive care, and patterns of clinical management were the main contributors to prolonged ICU stay. Identifying these factors can help optimize patient care, minimize complications, and alleviate healthcare costs within critical care settings, thereby informing the efficient allocation of resources.

  • Clinical Impact of Adjusted Valproic Acid Level in Patients with Hypoalbuminemia: A Single‐Center Cohort Study

    by Renad Bin Naheet, Khalid Al Sulaiman, Khuld Aloufi, Abdullah F. Alharthi, Mashael AlFaifi, Lama Nazer, Mohammad Shawaqfeh, Abdulmajeed M. Alshehri, Mohammed Abutaleb, Abdulaziz Alarifi, et al.

    Valproic acid (VPA) is highly protein‐bound, thereby impacting its free fraction and clearance in hypoalbuminemia. There is limited data on VPA use in such patients. Thus, this study evaluates the impact of adjusted VPA concentration (aVPAc) in predicting effectiveness and adverse effects compared to total VPA (tVPA) levels in hypoalbuminemic patients. A retrospective cohort study involved adult patients with seizures or epilepsy between January 1, 2016, and December 31, 2022. The levels of tVPA and aVPA (adjusted for albumin) were compared using receiver operating characteristic curves, and AUC differences were assessed using the DeLong method. Safety endpoints included hepatotoxicity, hyperammonemia, hyponatremia, and thrombocytopenia, while effectiveness endpoints were seizure occurrence, status epilepticus, and the use of additional antiepileptic medications during hospitalization. Of the 1621 screened patients, 71 with hypoalbuminemia received VPA. An aVPAc threshold of 154.19 mg/dL demonstrated higher sensitivity (86%) but lower specificity (47%) for predicting hepatotoxicity compared to a tVPA threshold of 67.53 mg/dL (sensitivity: 71%, specificity: 72%). Although aVPAc yielded a comparable negative predictive value (96% vs 95%), tVPA showed superior positive predictive value (25% vs 18%) and a higher Youden index (0.43 vs 0.33), indicating better overall discriminatory performance; however, these findings did not achieve statistical significance. In contrast, an aVPAc threshold of 188 mg/dL showed a sensitivity of 100% and a specificity of 82% for predicting hyperammonemia, which is superior to the tVPA threshold of 74.32 mg/dL that has a sensitivity of 40% and a specificity of 88%. The aVPAc also achieved a higher Youden index of 0.82 compared to 0.28 for tVPA. Adjusted VPA concentrations showed greater sensitivity than tVPA in predicting hepatotoxicity and hyperammonemia, suggesting potential utility for ruling out these adverse effects in hypoalbuminemic patients. Further research with a larger sample size is needed to validate these findings.

  • Open Access

    Evaluation of the clinical impact of de-escalated versus non-de-escalated antibiotics for the treatment of methicillin-susceptible staphylococcus aureus pneumonia in critically ill patients admitted to intensive care units: a multicenter cohort study

    by Khalid Al Sulaiman, Sufyan Mohammed Alomair, Aisha Alharbi, Rahaf Alqahtani, Asma A. Alshehri, Atheer O. Aldairem, Nada Alsuhebany, Khalid bin Saleh, Abdulaali R. Almutairi, Abdulmajeed A. Alzahrani, et al.

    Critically ill patients are at a higher risk of developing infections and related complications, which can lead to death. Each additional day of antipseudo

  • Open Access

    Managing Infections in Burn Patients: Strategies and Considerations for Antimicrobial Dosing

    by Abdullah F. Alharthi, Khalid Al Sulaiman, Sultan Alotaibi, Rahaf Alqahtani, Nader Damfu, Aisha Alharbi, Sufyan Alomair, Haifa A. Alhaidal, Ohoud Aljuhani

    Burn injuries are a major cause of morbidity and mortality, largely due to complications such as infection. Impairment of the immune system following burns increases susceptibility to both internal and external infections, underscoring the need for effective infection control strategies in burn care. In addition, burn patients frequently exhibit profound alterations in drug pharmacokinetics and pharmacodynamics (PK/PD), particularly during the resuscitation and hypermetabolic phases. In the resuscitation phase, increased capillary permeability and reduced cardiac output can prolong drug distribution, delay therapeutic response, lower peak plasma concentrations, and slow elimination. In contrast, the hypermetabolic phase is characterized by elevated catecholamine levels and enhanced tissue perfusion, which accelerate drug distribution and clearance. These physiological changes often necessitate antimicrobial dose adjustments to maintain therapeutic efficacy. This review emphasizes the critical importance of infection prevention and management in burn patients, with a focus on optimizing antimicrobial dosing and therapeutic monitoring in the context of PK/PD alterations.


  • Ethical, data security, and resource allocation considerations in AI integration for healthcare during Hajj: task force insights and future directions

    by Khalid Al Sulaiman, Abdullah F. Alharthi, Rahaf Alqahtani, Abdulrhman Aljouie, Anas Khan, Ahmed Al-Jedai, Abdulqader Almoeen, Mohammed Alshennawi, Hisham A. Badreldin, Lubna A. Alnasser, et al.


  • Evaluation of the Impact of Statin Therapy Intensity on the Risk of Delirium in Critically Ill Patients Admitted to ICUs: A Multicenter Cohort Study

    by Khalid Al Sulaiman, Renad Bin Naheet, Esraa Badawi, Ghazwa B. Korayem, Fatimah M. Abudayah, Ali F. Altebainawi, Mohamed A. Albekery, Ohud H. Bahari, Lulwah Al Turki, Ashjan Hadadi, et al.

    Background: Statins have well-established pleiotropic effects by interrupting delirium pathogenesis through their anti-inflammatory, immunomodulatory, and antithrombotic properties. The literature presents conflicting findings regarding the effects of statins on critically ill patients. It remains unclear whether the pleiotropic properties of statins and their influence on delirium are influenced by their lipophilicity, agent-specific, or statin intensity. This study aims to evaluate the impact of statin intensity on the risk of delirium in critically ill patients. Method: This is a multicenter, retrospective cohort study that included adult patients aged 18 years and older who received statin therapy and were admitted to the intensive care units (ICUs). Patients were categorized into high-intensity versus low-moderate intensity groups. The primary endpoint was the occurrence of delirium. The secondary endpoints were delirium recurrence during the same ICU admission, delirium-free days (DFDs) within 60 days, mortality, hospital and ICU length of stay. A propensity score (PS) matching procedure (SAS, Cary, NC) was used at a 1:1 ratio. Multivariable logistic regression was used to determine the adjusted p-value and odds ratio for outcomes. Results: After PS matching, a total of 1054 patients were included, 527 patients in each statin group. The odds of delirium and delirium recurrence were not significantly different between the two groups (OR: 1.10, 95% CI: 0.77, 1.57, P = 0.59 and OR: 0.92, 95% CI: 0.44,1.94, P = 0.84, respectively). Moreover, there was no statistically significant difference between the two groups in terms of delirium-free days (DFDs), mortality, and ICU length of stay. In contrast, patients who received the high-intensity statin had a significantly shorter duration of hospital length of stay than the low-intermediate group (beta coefficient: −0.12, 95% CI: (−0.23, −0.01), P = 0.04). Conclusion: The use of high-intensity statins in critically ill patients admitted to ICUs was not associated with a lower risk of delirium compared to low-moderate intensity statins. Further studies are required to confirm and explore various hypotheses and deepen the understanding of this correlation.

  • Open Access

    Charting the Path: A Strategic Roadmap for Early-Career Critical Care Pharmacists – A Review Focused on Professional Growth

    by Ohoud Aljuhani

    The field of critical care pharmacy is rapidly evolving, requiring specialized expertise to address the increasing complexities of intensive care unit environments. Early-career critical care pharmacists (ECCPs) are crucial to patient care, education, research, and leadership, but they often face challenges when transitioning from academia to practice. These challenges include limited hands-on training, a lack of mentorship, and the risk of burnout due to high clinical demands and insufficient institutional support. This review outlines a 5-year strategic plan for ECCPs, focusing on clinical, educational, scholarly, and professional growth. The plan highlights key milestones and practical steps to guide ECCPs in becoming skilled practitioners and leaders in critical care pharmacy. Strategies include structured mentorship, utilizing professional society resources, and promoting collaboration in research and leadership roles. Mentorship is identified as a cornerstone of ECCP development, providing professional, personal development, and networking opportunities. Professional societies, such as the Society of Critical Care Medicine, the American College of Clinical Pharmacy, the American Society of Health-System Pharmacists, and the Saudi Society of Clinical Pharmacy, offer mentorship frameworks, certifications, and resources to support ECCPs in refining their skills and achieving career progression. The strategic plan outlines a phased approach, beginning with foundational skills in Year 1, followed by advanced certifications and leadership roles in subsequent years. By the fifth Year, ECCPs are envisioned as mentors, researchers, and institutional leaders, shaping the future of critical care pharmacy. Also, this review underscores the importance of institutional and societal efforts to provide robust support mechanisms, ensuring ECCPs’ growth, job satisfaction, and long-term contributions to improved patient outcomes and the advancement of the specialty.

  • Open Access

    Evaluating the Effectiveness of a Multidisciplinary Virtual Clinic for Post-ICU Survivors: A Prospective Observational Study Protocol

    by Ohoud Aljuhani, Khalid Al Suilaman, Haifa Mesfer Algethamy, Mashael AlFaifi, Abdullah F. Alharthi, Rahaf A. Alqahtani, Samiah Abdullah Alsohimi, Fatimah Abudayah, Rashid Alballaa, Mohammed Alarifi, et al.

    The global ICU patient survival rate has increased dramatically due to advancements in critical care practices and technology; yet, post-ICU survivors frequently struggle with post-ICU syndrome (PICS), significantly affecting their overall health and well-being (Needham et al., 2012). The lack of structured post-ICU care in Saudi Arabia, coupled with a growing aging population and the ambitious Saudi Vision 2030, highlights the urgency of establishing innovative healthcare solutions. This protocol introduces a multidisciplinary virtual (tele) post-ICU follow-up clinic designed to address the unmet needs of ICU survivors. The clinic employs advancements in telemedicine, digital health, and multidisciplinary care to deliver comprehensive, accessible, and cost-effective support. Objectives include improving survivors' quality of life, reducing healthcare utilization, and enhancing care equity. Quantitative and qualitative methods will assess outcomes such as quality of life, cognitive and psychological recovery, and healthcare cost savings. This initiative not only addresses a critical gap in the healthcare system but also aligns with national goals to improve health outcomes and life expectancy.

  • Evaluation of Effectiveness and Safety of Dexmedetomidine in non-Mechanically Ventilated COVID-19 Critically ill Patients: A Multicentre Cohort Study

    by Ahmed Basilim, Khalid Eljaaly, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Wadha J. Aldhmadi, Abdulrahman Alissa, Mashael AlFaifi, Abdullah F. Alharthi, Ramesh Vishwakarma, et al.

    Background: Dexmedetomidine (DEX) is a highly favored sedative agent in critically ill patients owing to its anxiolytic and analgesic properties, lower risk of delirium, and minimal respiratory depression. Additionally, DEX exhibits anti-inflammatory properties, which have prompted its use in managing COVID-19 patients to mitigate cytokine storm and multi-organ dysfunction. Thus, this study aims to evaluate the safety and effectiveness of DEX use in critically ill patients with COVID-19. Method: This multicenter, retrospective cohort study included adult patients with confirmed COVID-19 who were admitted to the ICUs and did not require invasive mechanical ventilation (MV). Patients were categorized into two groups based on receiving DEX use within 72 h of ICU admission. The primary outcome was respiratory failure requiring invasive MV; other outcomes were considered secondary. Results: A total of 155 patients were included in the study after propensity matching. DEX did not reduce respiratory failure requiring invasive MV (HR 0.66; 95% CI (0.28, 1.53), P = .33). However, the time for invasive MV was statistically significantly shorter in the DEX group compared with the control group (beta coefficient (95%CI): - 1.05 (−2.03, −0.07), P = .03). In contrast, ICU and hospital Length of stay (LOS) were not statistically significant compared to the control group (beta coefficient 0.04 (95% CI −0.29, 0.38), P = .80, and beta coefficient - 0.03 (95% CI −0.33, 0.26), P = .81, respectively). In addition, the 30-day and in-hospital mortality rates were similar between the two groups (HR 1.1; 95% CI 0.97, 1.20, P = .14, and HR 1.01; 95% CI 0.95, 1.06, P = .90, respectively). Conclusion: Dexmedetomidine did not appear to lower the risk of respiratory failure necessitating invasive mechanical ventilation in critically ill patients. However, the mean time for invasive mechanical ventilation was shorter in the DEX group. Future interventional studies are required to confirm our findings.


  • Open Access

    Evaluating the effectiveness of nicotine replacement therapy in critically ill smokers: A meta-analysis of randomized controlled trials

    by Ohoud Aljuhani, Khalid Al Sulaiman, Hadeel Alkofide, Mashael AlFaifi, Asma A. Alshehri, Sarah Aljohani, Haifa Algethamy

    Introduction: The effectiveness of nicotine replacement therapy (NRT) in critically ill patients remains uncertain, as conflicting research results have been reported. Despite potential side effects and inconsistent data on safety and efficacy, NRT is still prescribed in intensive care units...